New FDA Groups For Rare, Neglected Diseases Could Speed Path To Market
This article was originally published in The Gray Sheet
Two new FDA review groups to recommend solutions for the prevention, diagnosis and treatment of rare diseases and neglected diseases of the developing world would help get treatments to market faster, patient advocates and lawmakers say
You may also be interested in...
The Foundation for Innovative New Diagnostics is working with the diagnostics industry to create faster, more cost-effective tests for drug-resistant tuberculosis in developing countries
As Bharat Biotech prepares its COVID-19 vaccine for a launch in the quarter ending next 30 September and claims at least 60% efficacy, questions arise over why trials were not temporarily halted following a serious adverse event during Phase I and why this wasn’t disclosed to participants in subsequent studies.
Highlighting progress it has made over the past few years, Japan’s regulatory agency says it wants to raise even further the number of “Japan-first” approvals, as part of its stated mission to get safe and effective new drugs to patients more quickly.